Pegulicianine Acetate

CHEMBL4594345 Phase 4 Одобрено Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

A fluorescent imaging agent used during surgery to help surgeons visualize cancer tissue in real time, improving the ability to remove breast cancer tumors with clear margins. It is activated by a special light source used intraoperatively.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Часто задаваемые вопросы

A fluorescent imaging agent used during surgery to help surgeons visualize cancer tissue in real time, improving the ability to remove breast cancer tumors with clear margins. It is activated by a special light source used intraoperatively.

Yes, Pegulicianine Acetate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4594345. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

PillFYI

Ищете информацию, доступную для пациентов?

Pegulicianine Acetate на PillFYI

Краткие Данные

Внешние ссылки

ChEMBL CHEMBL4594345

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Медицинский отказ от ответственности

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.